Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
6.91
-3.33 (-32.52%)
At close: Dec 17, 2025, 4:00 PM EST
7.08
+0.17 (2.46%)
After-hours: Dec 17, 2025, 7:59 PM EST
Kyverna Therapeutics Employees
Kyverna Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 16 or 16.67% compared to the previous year.
Employees
112
Change (1Y)
16
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,437,429
Market Cap
302.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Dec 31, 2023 | 96 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KYTX News
- 9 hours ago - Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript - Seeking Alpha
- 12 hours ago - Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock - GlobeNewsWire
- 1 day ago - Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing - Seeking Alpha
- 1 day ago - Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 2 days ago - Kyverna Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 days ago - Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome - Seeking Alpha
- 2 days ago - Kyverna's cell therapy meets main goal of mid-stage study - Reuters
- 2 days ago - Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome - GlobeNewsWire